$1.50
-0.04 (-2.60%)
Open$1.51
Previous Close$1.54
Day High$1.56
Day Low$1.50
52W High$43.95
52W Low$34.76
Volume—
Avg Volume122.9K
Market Cap61.68M
P/E Ratio49.75
EPS$0.77
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,833.3% upside
Current
$1.50
$1.50
Target
$44.00
$44.00
$29.80
$44.00 avg
$55.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.74M | 5.58M | 6.05M |
| Net Income | 1.11M | 1.28M | 1.11M |
| Profit Margin | 19.3% | 22.9% | 18.3% |
| EBITDA | 2.54M | 2.28M | 2.52M |
| Free Cash Flow | 874.9K | 1.03M | 1.03M |
| Rev Growth | +19.1% | +13.5% | +5.7% |
| Debt/Equity | 1.60 | 1.67 | 1.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |